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Abstract
Recurrent tuberculosis (TB) following successful treatment constitutes a significant challenge
to TB control strategies. TB recurrence can be due to either reactivation of the same strain,
i.e., relapse, or reinfection with a new strain. Recurrence due to reinfection has become an
area of intense study due to its perceived significance in TB endemic settings with high rates
of human immunodeficiency virus (HIV) coinfection. This review presents a descriptive
analysis of recurrent TB disease and explores risk factors, immunopathogenesis, treatment,
and preventative strategies. Currently available laboratory methods used to discriminate
tuberculosis recurrence due to reinfection and relapse are discussed. We highlight risk
factors for recurrence and strategies for early detection of TB recurrence. Enhanced treat-
ment options such as intensified initial treatment, extension of treatment, and secondary
preventative therapy for patients presenting with multiple risk factors are explored in this
review. The potential value of identifying immunological correlates of risk and protection in
recurrent TB is also briefly examined.
Keywords: recurrence, tuberculosis, relapse, reinfection, molecular typing
1. Introduction
Tuberculosis remains one of the most significant public health challenges globally, despite
significant advances in tuberculosis (TB) control [1]. Approximately one-third of the world’s
population is estimated to harbor latent forms of the Mycobacterium tuberculosis (MTB) bacilli,
creating a reservoir for future disease. The alarmingly high TB incidence and prevalence rates
in countries that also have a high background prevalence of human immunodeficiency virus
(HIV) have been persistent for more than a decade. The interplay between HIV infection and
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TB has resulted in 10 times greater risk of TB reactivation from latent disease in coinfected
individuals. In addition to the increased risk of TB reactivation disease, HIV coinfection has
also been reported to substantially increase the rate of recurrent TB disease from reinfection
due to the increased vulnerability of immune-compromised patients to TB infection [2, 3].
Recurrent TB disease occurs when patients who were previously treated for TB develop a
new disease episode, due to either relapse (recurrence of the old infection) or reinfection
(infection with a new strain) [4]. Recurrent TB disease is associated with poor treatment out-
comes and higher mortality rates compared to primary TB infection [5]. Clinical, epidemiolog-
ical, and/or microbiological data cannot be used to differentiate relapse and reinfection.
Distinguishing between the two mechanisms requires evaluating the homology of the MTB
strains isolated during the first and subsequent TB episode using molecular DNA fingerprint-
ing technology [4].
In TB-endemic settings experiencing high rates of HIV coinfection, the rate of recurrent TB is
significantly increased. Recurrence rates of up to 24.4% have been reported in HIV/TB-
coinfected individuals, with most recurrences occurring within 2 years of successful treatment
completion [5]. Prior to the development of DNA fingerprinting technology, primary TB
disease was thought to impart some measure of immunity and subsequent TB infection was
the result of reactivation of the strain from the original episode of infection [4]. However, with
the advent of DNA fingerprinting techniques, numerous studies have explored the roles of
relapse and reinfection in TB recurrence [6]. In countries with a high incidence of TB, reinfec-
tion has been reported as the main driver of recurrent TB, with molecular studies reporting up
to 88% of TB recurrences due to reinfection in HIV-coinfected patients. In contrast, countries
with a low TB incidence have reported TB relapse as the main cause of recurrent TB disease [7].
Current World Health Organization (WHO) guidelines use the term “relapse” to describe all
TB recurrences during programmatic assessments. The term is largely generic and incorpo-
rates recurrence due to relapse or reinfection. The two mechanisms of TB recurrence exist as
fundamentally independent forms of TB infection, have differing pathogenesis, and have
different implications for patients and TB control programs [6, 7]. Relapse is associated with
treatment failure and may be due to either clinical management complexities leading to
subtherapeutic drug concentrations of key TB drugs due to drug–drug interactions or altered
drug metabolism or from patient-related factors such as poor treatment adherence. Further-
more, relapse disease has been associated with an increased risk of acquiring drug-resistance
in the infecting strain of MTB. Higher rates of TB relapse seen in HIV-infected patients may
indicate the need for lengthier, more aggressive treatment to eliminate MTB infection com-
pared to standard practice. High rates of reinfection are reflective of poor public health
interventions that fail to reduce community transmission [3]. In the context of HIV coinfection,
reinfection has been associated with failure to develop protective immunity after the first
episode of TB resulting in this subset of patients bearing a higher susceptibility to reinfection
with MTB [8]. The aim of the current review was to examine the disease burden due to
recurrent TB disease and explore the risk factors, immunopathology, treatment, and preven-
tion and the relative contribution of relapse versus reinfection to TB recurrence.
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2. Epidemiology of recurrent TB
Population-based surveillance reports on the rates of recurrent TB following completion of
anti-TB treatment are lacking. Recent estimates of recurrent TB across various regions indicate
an average of 2290 cases/100000 person-years at 12 months following treatment completion. In
high-incidence settings, this rate is as high as 7850 cases/100000 person-years [8]. An earlier
report by Panjabi et al. analyzing 32 studies reported an overall recurrence rate of 3010 and
2290 per 100,000 person-years following 6 and 12 months of treatment, respectively, among
controlled trials. They also reported that these rates were higher for observational studies
compared to controlled trials. Rates were also reported to be higher in countries with high TB
incidence [5]. Recurrence rates for specific regions have been emerging; many of which are
demarcated as WHO high-burden countries. Glynn et al. reported a recurrence rate of 24.4
cases per 100 person-years in HIV-positive individuals and 4.7% per 100 person-years in their
HIV-negative counterparts [9]. Charalambous et al. reported an overall recurrence rate of
7.89% per 100 person-years in the same setting among a mining population. The recurrence
rate was higher in HIV-positive individuals at 8.86 cases per 100 person-years compared to
3.35 cases per 100 person-years in HIV-negative counterparts [10]. Narayanan et al. reported a
recurrence rate of 14% among an HIV/TB-coinfected cohort of 306 patients from South India.
Among the patients with recurrent TB, 88% of recurrent infections were due to reinfection [11].
Sun et al. reported a recurrence rate of 35 cases per 1000 person-years for patients with drug-
sensitive TB and 65 cases per 1000 person-years among patients with drug-resistant TB [12].
Luzze et al. reported an overall recurrence rate of 8.4 cases per 100 person-years in a cohort
from Uganda. The recurrence rate was also reported to be higher among HIV-positive individ-
uals at 9.4 cases per 100 person-years compared to 6.7 cases per 100 person-years in HIV-
negative counterparts [13]. Vree et al. reported a recurrence rate of 8.6% among a Vietnamese
cohort of 244 patients [14]. Datiko et al. reported a recurrence rate of one case per 100 person-
years (15 recurrent cases in 368 patients – 4.1%) among an Ethiopian cohort [15]. Moosazadeh
et al. reported a recurrence incidence of 8.3% in Iran [16]. Crofts et al. reported the recurrence
rate in England and Wales as 4.1 cases per 100 person-years; however, in HIV-positive individ-
uals, this rate was reported as 7.6 cases per 100 person-years [17].
3. Definitions and terminology
Definitions of terms relating to recurrent TB disease that feature in this review are given below
and some are illustrated in Figure 1.
3.1. Latent TB infection (LTBI)
LTBI is defined as a state of disease in which MTB persists within the host and is associated
with damage that is evident at a cellular or tissue level but is not associated with the disease.
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While this form of disease displays no clinical or radiological evidence of active disease, viable
MTB bacilli are contained within tissues [18].
3.2. Primary TB disease
Primary TB is defined as disease occurring in a patient who has never been treated for TB or
who has received less than 1 month of anti-TB treatment. In some instances, primary TB refers
to the initial exposure of MTB; thereafter, the reactivation of TB disease following a period of
clinical latency is referred to as postprimary or TB occurrence. In the current review, we refer to
primary TB in accordance to the WHO definition [19].
3.3. Recurrent TB disease
Recurrent TB disease is defined as the diagnosis of a subsequent episode of TB following
treatment completion or cure at the end of the most recent course of treatment. Recurrent TB
disease occurs after the initial TB disease episode has been classified as clinically cured.
According to WHO guidelines, cure is defined as smear and culture negative sputum samples
from the last month of treatment and on at least one previous occasion [19].
3.4. TB relapse
Relapse disease is defined as a subsequent episode of TB disease due to the reactivation/
reemergence of the original infecting strain of MTB, determined by genotypic homogeneity
assessment of primary and recurrent MTB strains [4]. Given that MTB strains are highly
homogenous by nature, combined with high rates of transmission, classification of relapse
infection is challenging [20].
Figure 1. The continuum ofMycobacterium tuberculosis (MTB)–host interaction following MTB infection. Successful cure is
achieved in ~95% of patients. In ~5% of patients, this cycle extends beyond successful treatment completion when the
cycle of TB recurrence occurs either through (a) relapse of the original infection or (b) reinfection by new strain of MTB.
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3.5. TB reinfection
Reinfection is defined as a subsequent episode of TB disease due to the exogenous infection
with an MTB strain that is distinct from the organism that caused the original infection [4]. A
challenge regarding detection of reinfection is that in high TB-endemic settings, patients
maybe exposed to be reinfected with a very similar strain that caused the primary infection,
making differentiation between relapse disease and reinfection difficult.
4. Clinical presentation of recurrent TB
The symptoms of recurrent TB have been reported to vary in clinical and radiologic symptoms
and are clinically indistinguishable from primary TB disease [21]. In general, TB symptoms are
usually gradual in onset and duration and may vary from a few weeks to months. However, in
young children and patients with HIV coinfection, a more acute onset of disease has been
recorded. Typical symptoms such as fever, night sweats, and weight-loss occur among approx-
imately 75, 45, and 55% of patients, respectively. The presence of a persistent nonremitting cough
has been cited as the most common symptom, recorded in approximately 95% of patients with
TB. Patients with cavitary lung disease, synonymous with recurrent TB disease, typically present
with chronic cough, mostly accompanied by fever and/or the presence of night sweats and
weight loss. The associated cough may be productive or nonproductive in nature. The sputum
produced by patients maybe mucoid, mucopurulent, and bloodstained or may have severe
hemoptysis. Other symptoms include chest pain and dyspnoea. Chest X-ray plays a critical role
in diagnosis of sputum smear-negative patients [22]. Figure 1 depicts the radiological progres-
sion of initial drug-susceptible TB (Figure 2a), followed by a recurrent TB episode (Figure 2b,
diagnosis, and Figure 2c, end of treatment for recurrent TB). Typical chest radiograph findings
include old fibrotic lesions, often cooccurring with other nonspecific features of tuberculosis such
as lobar opacities, consolidation, fibrosis, and interstitial infiltrates. Severely immune-suppressed
Figure 2. Chest X-rays of a patient with initial drug-sensitive TB, subsequently developed drug-resistant TB, depicting:
(a) cavities and infiltrates in both lungs; (b) cavities and infiltrates on the right lung and fibrosis in the left lung; and
(c) cavities, infiltrates, and patchy consolidation in right lung and consolidation in mid and lower zones of the left lung.
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patients and young children are less likely to present with pathology on chest radiograph [22]. In
the context of continuing disease due to poor adherence, recurrent TB is diagnosed by the clinical
process, sputum smear microscopy, and chest radiograph [21]. Furthermore, the two mecha-
nisms of recurrent TB are clinically indistinguishable and require specialized strain typing to
differentiate between relapse and reinfection [4].
5. Methodology used to study recurrent TB
Discriminating TB reinfection from relapse through the study of the MTB genome using
various laboratory methods is a key hallmark in the study of recurrent TB. DNA fingerprinting
techniques are based on genomic variation, forming the basis of molecular epidemiological
studies. The genome of the MTB complex is largely conserved with the presence of monomeric
sequences repeated periodically, known as repetitive units. There are two types of repetitive
units, namely, interspersed repeats (IR) and tandem repeats (TR). The former occur throughout
the genome in the form of direct repeats and insertion sequences, while the latter are a series of
head-to-tail direct uninterrupted repeats in the form of variable number tandem repeats
(VNTR). The most common techniques used to distinguish between the two mechanisms of
TB recurrence include IS6110-restriction fragment length polymorphism (IS6110-RFLP) analy-
sis, mycobacterial interspersed repetitive-unit variable number of tandem repeats (MIRU-
VNTR) typing, and spacer oligonucleotide genotyping (spoligotyping) [4, 23]. More recently,
whole genome sequencing (WGS) has been used to compare strains representing different
episodes of TB infection. One of the challenges associated with the former typing methods is
the interpretation of similar isolates in the case of relapse disease. There is no standard for
interpretation of changes in banding patterns when comparing specimens from different
episodes of disease. It is suggested that identical bands or a difference of one band is good
approximation for defining relapse. The use of WGS surmounts this issue by directly evaluat-
ing the number of single nucleotide polymorphism (SNP) differences between the disease
episodes. There is still some uncertainty regarding the appropriate SNP cutoff value, which
depends on the analysis platform and genome coverage. However, WGS is more robust as it
excludes mixed infections and allows genomic associations with relapse and reinfection to be
examined directly [8, 24, 25].
5.1. IS6110 RFLP typing
IS6110 RFLP is a well-validated method used extensively for MTB typing. This method relies
upon the IS6110 insertion element as a genetic marker was long recognized as the gold
standard for studying the molecular epidemiology of MTB [26, 27]. The IS6110 insertion
element has proven stable in vitro and in vivowith low transpositional frequency and is present
in up to 25 copies in MTB. Strain identification using this method relies on variation in both the
number and location of IS6110 elements in the MTB genome. The restriction endonuclease
PvuII cleaves the IS6110 element once by recognizing a particular palindromic sequence. The
result is thousands of DNA fragments of different lengths that are then separated according to
size by gel electrophoresis. Notably, different molecular weight fragments arise because of the
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varying distances between insertion sequences, which create a specific banding pattern char-
acteristic of that isolate. Dendograms are constructed to graphically represent the similarity
coefficients between isolates, allowing them to be clustered into groups based on banding
patterns. Visual inspection can then be used to decide which isolates among these groups are
identical or differ by only one or two bands. The IS6110 method has been standardized
enabling comparison of fingerprints globally. Thus, IS6110 RFLP genotyping can provide a
comparison of the strains involved at the initial and recurrent TB episodes by comparing the
fingerprint patterns. MTB isolates with identical IS6110 DNA fingerprints or slight variations
in banding patterns identify relapse of a prior infection, while distinct fingerprints identify
reinfection with a new strain of MTB [26–28]. Challenges of utilizing this typing technique
includes lower discriminatory power in isolates with low copy numbers of the IS6110 element,
usually less than six copies of the element, the high level of expertise required for the technique
and analysis, and poor reproducibility of the technique. Furthermore, strains displaying iden-
tical IS6110 banding patterns have been reported to display unique genetic identities in the
presence of a secondary technique [4].
5.2. MIRU-VNTR typing
MIRU-VNTR typing is a PCR-based technique followed by detection by capillary electropho-
resis, which characterizes both the number and sizes of variable tandem repeats in 12 or more
loci. The repeat number is highly variable in many loci and is therefore termed “variable
number tandem repeat” loci. They consist of small repetitive sequences of 40- to 100-bp and
are unique in nature. They are scattered in 41 locations in the genome of MTB and are present
mainly in the intergenic regions. The principle of this method is PCR amplification of 12- to 24-
VNTR loci using primers complementary to the flanking regions, followed by gel electropho-
resis. The size of the PCR amplicon reflects the tandem repeat unit, which is then converted
into a numerical code to get a digital format in which each digit represents the number of
copies present at that locus. This method utilizes variations in repetitive sequences, which are
not under selective pressure and evolve relatively rapidly making it an ideal tool for molecular
epidemiological studies. The discriminatory power of MIRU-VNTR is proportional to the
number of loci included. MIRU-VNTR typing using a standardized set of 24 loci is now the
international standard and is currently employed in European countries and globally. This
method is rapid, reproducible, and cheaper than RFLP typing. Historically, this method was
widely used in its 12-loci format that had a lower discriminatory power compared to IS6110
RFLP [4, 23].
5.3. Spoligotyping
Spoligotyping is a hybridization assay that detects variability in genomic direct repeat (DR)
locus of the MTB complex. The DR region of MTB consists of multiple copies of a conserved
36 bp sequence region (the DRs), which are separated by multiple unique spacer sequences.
This method involves PCR amplification of the entire DR locus using primers that are comple-
mentary to the flanking spacer sequences, followed by hybridization to a membrane with
43 spacer oligonucleotides. The resulting bands produce a dark band in the presence of a
spacer or no band if a spacer is absent. The pattern is converted into a 43 digit binary code
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and subsequently converted into a 15 digit octal code. This code is unique and represents a
specific banding pattern. This is a simple, high-throughput method that is cost-effective. It is,
however, less discriminatory than RFLP typing. This method is ideal as a first-line screening
tool, to be followed by other typing methods if needed [4, 23].
5.4. Whole genome sequencing
WGS analysis has been widely applied to the field of molecular epidemiology in the last decade.
WGS plays a significant role in examining outbreaks and identifying transmission events where
strains are genetically indistinguishable by conventional methods. WGS-based genotyping offers
the optimal resolution of MTB complex isolates and holds the advantage of generating addi-
tional data, such as drug resistance [25]. Byrant et al. recently demonstrated the higher discrim-
inatory power of WGS compared to MIRU-VNTR to differentiate relapse from reinfection. The
decreasing cost of this platform, coupled with advances in genomics, makes WGS the most
desirable single analysis tool for identification, prediction of drug resistance, and epidemiologi-
cal typing. WGS also has a significant role in detecting MTBmixed strain infections. This method
is set to become the gold standard for typing in the near future [24].
6. Relapse and reinfection
Published studies also vary in reported rates of TB disease due to reinfection from as low as
<3–>60%. An earlier review by Lambert et al. failed to show a consistent trend when reporting
whether TB recurrence is due to relapse versus reinfection [6]. Unsurprisingly, recurrence due
to TB reinfection has been reported to be the main mechanism of recurrent TB disease in
geographical regions with a high burden of TB disease; however, high rates of reinfection have
also been reported from low- and moderate-incidence settings. Conversely, a poor association
between reinfection and recurrent TB disease in high-burden settings has also been reported.
This highlights that a consistent trend in recurrent TB disease is lacking [8, 10, 11, 24, 29–59].
Studies indicate that relapse generally occurs within a year following treatment, while reinfec-
tion predominates after the first year following treatment [8, 52]. In the context of HIV coinfec-
tion, there is a 2.4 times higher hazard ratio for recurrent TB disease, in comparison to HIV-
uninfected individuals. HIV coinfection and antiretroviral treatment have been associated with
an increased risk of recurrent TB due to reinfection [41, 47]. In a 13-year study conducted in
Cape Town, South Africa, TB relapse rate peaked at 3.93% (95% confidence interval [CI], 2.35–
5.96%) per annum 0.35 (95% CI, 0.15–0.45) years after treatment completion, whereas reinfec-
tion tuberculosis rate peaked at 1.58% (95% CI, 0.94–2.46%) per annum 1.20 (95% CI, 0.55–1.70)
years after completion [52]. Reports of higher rates of TB reinfection may occur inadvertently
likely due to laboratory contamination resulting in incorrect classification, mislabeling of iso-
lates, mixed strain infections, varying clinical and radiological profile of patients, and length of
follow-up. Varying lengths in the follow-up period make it difficult to make comparisons
between studies. Table 1 details published studies distinguishing reinfection from relapse in
their reporting recurrent TB disease.
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Author,
publication
year
Country Study design Number
of
patients
analyzed
Recurrences
(Total)
With
fingerprinting
resultsa
Reinfection
(% of a)
Strain typing
method
HIV
status
Comment
Hawken et al.
(1993)c [29]
Kenya Prospective
cohort
196 11 3 1 (33) NA HIV
infected
and
uninfected
Increased recurrence rate (34-fold
higher) in HIV-infected group
compared to HIV-uninfected
counterparts. Thiacetazone-
containing regimen was used for
treatment. Study not powered to
determine the relative contribution
of relapse or reinfection to TB
recurrence.
Das et al.
(1993)c [30]
Hong
Kong
Retrospective
analysis RCT
NA Not reported 42 5 (12) IS986-RFLP
and phage
typing
Not
reported
Monthly sputum cultures were
analyzed over a two-year period.
Only 5 patients showed distinct
differences in serial isolates.
Detection of possible mixed
infection, given the heterogeneity
detected among serial samples. No
HIV data or risk factors reported.
Godfrey-
Faussett et al.
(1994)c [31]
Kenya Retrospective
cohort
NA Not reported 5 1 (20) NA HIV
infected
and
uninfected
Study not powered to determine the
relative contribution of relapse or
reinfection to TB recurrence. No risk
factors reported.
Das et al.
(1995)c [32]
India Retrospective
analysis RCT
NA 30 13 3 (23) IS6110-RFLP Not
reported
The main objective of the study was
to determine the utility of IS6110-
RFLP to distinguish between relapse
and reinfection in recurrent TB.
Sahadevan
et al. (1995)c
[33]
India Retrospective
analysis RCT
52 44 29 9 (31) IS6110-RFLP Not
reported
The main objective of the study was
to modify the IS6110-RFLP assay
using a direct repeat probe to
increase its ability to distinguish
between relapse and reinfection in
recurrent TB.
El-Sadr et al.
(1998)c [34]
USA RCT NA 2 1 1 (100) NA HIV
infected
The main aim of the study was to
determine the efficacy of levofloxacin
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Author,
publication
year
Country Study design Number
of
patients
analyzed
Recurrences
(Total)
With
fingerprinting
resultsa
Reinfection
(% of a)
Strain typing
method
HIV
status
Comment
and
uninfected
to the standard treatment regimen
for drug-susceptible TB. The
addition of levofloxacin resulted in
low relapse rates, thus small sample
size.
Vernon et al.
(1999)c [35]
USA RCT 71 8 7 0 (0) IS6110-RFLP HIV
infected
This was an early study aimed at
assessing the a once-weekly regimen
of isoniazid and rifapentine with
twice-weekly isoniazid and rifampin
in the continuation phase of
treatment for pulmonary
TB in HIV-infected and -uninfected
patients. The current report assessed
only the HIV-infected cohort.
Relapse TB was associated with an
increase in rifamycin resistance.
Van Rie et al.
(1999)c [36]
South
Africa
Retrospective
analysis-lab
database
698 48 16 12 (75) IS6110-RFLP HIV
uninfected
High-TB endemic setting. All
patients in the cohort were reported
to be HIV-uninfected. Reinfection
was reported to occur within 7 to
8 months of previous cure.
Reinfection in a high-endemic area in
HIV-uninfected patients, probably
due to the increased risk of
developing recurrent TB after
primary infection.
Johnson et al.
(2000)c [37]
Uganda Prospective
cohort
291 17 4 0 (0) IS6110-RFLP HIV
infected
and
uninfected
The main aim of the study was to
assess the efficacy of an
unsupervised, rifampicin-containing
regiment for drug-susceptible TB in
HIV-infected adults. No cases of
reinfection. Relapse is probably an
indication of the new regimen failing
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Author,
publication
year
Country Study design Number
of
patients
analyzed
Recurrences
(Total)
With
fingerprinting
resultsa
Reinfection
(% of a)
Strain typing
method
HIV
status
Comment
or poor adherence in the current
study.
Lourenco et al.
(2000)c [38]
Brazil Retrospective
cohort
32 12 12 3 (25) DRE-PCR
and IS6110-
RFLP
HIV
infected
The study aimed to assess the
relative contribution of relapse and
reinfection in HIV-coinfected
patients with recurrent TB. Study
was not powered to assess the
contribution of HIV. Among the
three patients with reinfection, all
were unique strains.
Caminero et al.
(2001)c [39]
Gran
Canaria
Island
Retrospective
population
based-cohort
92 23 18 8 (44) IS6110-RFLP HIV
infected
and
uninfected
The study setting has a moderate
incidence of tuberculosis. Reinfection
was attributed to TB recurrence in
both HIV-infected and -uninfected
patients. A dominant strain was
reported for reinfection and relapse.
Relapse was associated with
increased drug resistance.
Bandera et al.
(2001)c [40]
Italy Prospective
population
based-cohort
2127 32 32 5 (16) IS6110-RFLP HIV
infected
and
uninfected
Low TB incidence setting. Two of the
five cases of reinfection were
associated with drug resistance
during recurrent TB episode, and
three cases represented dominant
strains circulating in the setting.
Higher risk of relapse was described
for HIV-infected and MDR-TB
patients.
Sonnenberg
et al. (2001)c
[41]
South
Africa
Prospective
population
based-cohort
miners
65 65 39 14 (36) IS6110-RFLP HIV
infected
and
uninfected
Thirteen of the fourteen recurrences
occurred within 6 months of follow-
up were attributed to relapse. HIV
coinfection was cited as a strong risk
factor for recurrence due to
reinfection. Residual cavitation was
also attributed to recurrent disease.
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Author,
publication
year
Country Study design Number
of
patients
analyzed
Recurrences
(Total)
With
fingerprinting
resultsa
Reinfection
(% of a)
Strain typing
method
HIV
status
Comment
Gracia de
Viedma et al.
(2002) [42]
Spain Retrospective
population
based-cohort
2567 172 43 14 (33) DRE-PCR;
spoligotyping
HIV
infected
and
uninfected
Low TB incidence and low exposure
MTB, relapse was the main cause of
recurrence. Patients displayed poor
anti-TB treatment adherence. No
association with HIV.
Fitzpatrick
et al. (2002)
[43]
Uganda Retrospective
population
based-cohort
1100 40 40 9 (23) Not reported HIV
infected
and
uninfected
Low HIV incidence setting, main
cause of recurrence was relapse.
Three of the four HIV-infected
patients were reinfected with MTB.
The remaining patient was sputum
smear negative.
Lan et al.
(2002) [44]
Vietnam Retrospective
population
based-cohort
2901 168 39 0 (0) IS6110-RFLP Not
reported
Primary MDR-TB was cited as a risk
factor for relapse, associated with the
Beijing strain. However, the study
was not powered to detect risk
factors related to relapse.
El Sahly et al.
(2003) [45]
USA Retrospective
population
based-cohort
Not
reported
100 38 8 (21) IS6110-RFLP
and
spoligotyping
HIV
infected
and
uninfected
Low TB incidence setting. Relapse
was the main driver of recurrence,
with increased in drug resistance in
the recurrent episode of TB. Only
two of the eight patients with
reinfection were HIV infected.
Jasmer et al.
(2004) [46]
Canada,
USA
RCT 1244 79 75 3 (4) IS6110-RFLP HIV
infected
and
uninfected
High levels of reinfection despite
Canada and USA having low TB
incidence.
Verver et al.
(2005) [47]
South
Africa
RCT 447 61 31 24 (77) IS6110-RFLP HIV
infected
included
Recurrence following successful
treatment as per definition of this
review. Reinfection not stratified by
HIV status.
Scaaf et al.
(2005) [48]
South
Africa
Prospective
cohort
87 9 4 1 (25) IS6110-RFLP HIV
infected
Pediatric population. Reinfection
described in one patient; analysis of
episode 1 and 3 of TB. Two further
Tuberculosis
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Author,
publication
year
Country Study design Number
of
patients
analyzed
Recurrences
(Total)
With
fingerprinting
resultsa
Reinfection
(% of a)
Strain typing
method
HIV
status
Comment
cases of reinfection defined by
epidemiologic data and DST.
Shen et al.
(2006) [49]
China Retrospective
population
based-cohort
202 54 52 32 (62) IS6110-RFLP;
MIRU-VNTR
Not
reported
Data on HIV status not available;
however, low HIV incidence setting
(0.6 cases/100,000 person-years). No
time interval defined between end of
treatment and new episode of TB.
Cacho et al.
(2007) [50]
Spain Retrospective
population
based-cohort
645 20 8 1 (13) IS6110-RFLP;
MIRU-VNTR
HIV
infected
and
uninfected
Patient with TB reinfection was HIV
negative. Relapse was attributed to
recurrent TB in this setting. No
differences in risk factors reported
for relapse and reinfection.
Charalambous
et al. (2008)
[10]
South
Africa
Mining
population
609 57 16 11 (69) IS6110-RFLP HIV
infected
and
uninfected
Among the HIV-positive group, 10 of
the 14 recurrences were due to
reinfection. However, only two pairs
available in the negative group. One
case of reinfection and one case of
relapse.
Narayanan
et al. (2009)
[11]
India Prospective
population
based-cohort
Not
reported
74 48 44 (92) IS6110-RFLP;
MIRU-
VNTR;
spoligotyping
HIV
infected
and
uninfected
Reinfection was cited as the main
cause of recurrence in HIV-infected
patients (88%), while relapse was the
main cause of recurrence in HIV-
uninfected counterparts (91%).
Bang et al.
(2009) [51]
Denmark Retrospective
population
based-cohort
4154 73 73 19 (26) IS6110-RFLP Not
reported
The risk of TB recurrence by
reinfection increased with time. No
data available for risk factors
contributing to recurrence.
Marx et al.
(2010) [52]
South
Africa
Retrospective
population
based-cohort
309 203 130 66 (51) IS6110-RFLP HIV
infected
and
uninfected
Relapse and reinfection not stratified
by HIV status. Relapse occurred
early after treatment completion,
while reinfection occurred ≥1 year of
treatment completion.
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Author,
publication
year
Country Study design Number
of
patients
analyzed
Recurrences
(Total)
With
fingerprinting
resultsa
Reinfection
(% of a)
Strain typing
method
HIV
status
Comment
Crampin et al.
(2010) [53]
Malawi Long-term
cohort
584 53 39 13 (33) IS6110-RFLP HIV
infected
and
uninfected
Reinfection was cited as the main
cause of recurrence in HIV-infected
patients (52%), while relapse was the
main cause of recurrence in HIV-
uninfected counterparts (93.7%).
Vargese et al.
(2012) [54]
Saudi
Arabia
Retrospective
population-
based cohort
Not
reported
223 223 39 (17) MIRU-VNTR Not
reported
14% of reinfection cases were
associated with resistance to ≥1 first-
line drug.
Bryant et al.
(2013) [24]
Malaysia,
South
Africa, and
Thailand
Sub-study of
RCT
Not
reported
50 36 3 (9) MIRU-VNTR
and WGS
HIV
infected
and
uninfected
Main objective of the substudy was
to determine the role of WGS to
distinguish relapse from reinfection.
Guerra-
Assuno et al.
(2014) [8]
Malawi Prospective
population-
based cohort
1471 139 75 20 (26) IS6110-RFLP
and WGS
HIV
infected
and
uninfected
Reinfection was most common in
HIV-infected patients. Relapse was
associated with an increased
prevalence of isoniazid resistance.
Interrante et al.
(2015) [55]
USA Population-
based cohort
3039 136 136 20 (15) IS6110-RFLP;
MIRU-VNTR
HIV
infected
and
uninfected
18 of the 136 cases of recurrence TB
were HIV infected. Of these, four
cases were attributed to reinfection.
Schiroli et al.
(2015) [56]
Italy Prospective
cohort study
4682 83 83 19 (23) IS6110-RFLP;
MIRU-VNTR
HIV
infected
and
uninfected
No causal association with HIV
status. Increased drug resistance in
patients with recurrent TB.
Korhonen et al.
(2016) [57]
Finland Population-
based cohort
8299 48 21 3 (14) WGS based
spoligotyping
HIV
infected
and
uninfected
Low rate of HIV coinfection in cohort
(1/21). The difference in the number
of SNPs in relapse isolates was
reported to be 0–6. In the presence of
dominant strain types, reinfection
cannot be ruled out. In one case of
relapse, the difference in the number
of SNPs was reported to be 38 over a
2-year period.
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publication
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Recurrences
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With
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resultsa
Reinfection
(% of a)
Strain typing
method
HIV
status
Comment
Shen et al.
(2017) [58]
China Retrospective
population-
based cohort
13,417 710 141 59 (42) IS6110-RFLP;
MIRU-VNTR
Not
reported
Low HIV prevalence in the study
setting. Patients with cavitation,
diabetes, and initial drug resistance
were at high risk for recurrent TB.
Reinfection contributed to a
significant number of cases.
Whitney et al.
(2017) [59]
Southern
Africa
Substudy of
RCT
Not
reported
51 35 3 (9) MIRU-VNTR
and WGS
Not
reported
Main objective of the substudy was
to determine the role of WGS to
distinguish relapse from reinfection.
The difference in the number of SNPs
in relapse isolates was reported to be
0–5.
aTotal number of recurrent TB episodes within the cohort.
bPercentage of recurrent TB episodes caused by reinfection (calculated from a).
cAdapted from the systematic review by Lambert et al. [6]
Abbreviations: DRE-PCR, double repetitive element-polymerase chain reaction; DST, drug susceptibility profile; MDR-TB, multidrug resistant-tuberculosis; MIRU-VNTR,
mycobacterial interspersed repetitive unit-variable number tandem repeats; MTB, Mycobacterium tuberculosis; RCT, randomized controlled trial; RFLP, restriction fragment
length polymorphism; SNP, single nucleotide polymorphism.
Table 1. Studies conducted on recurrent tuberculosis infections, distinguishing the contribution reinfection versus relapse.
Insights into Recurrent Tuberculosis: Relapse Versus Reinfection and Related Risk Factors
http://dx.doi.org/10.5772/intechopen.73601
17
7. Risk factors for recurrent TB
Trinh et al. outlined risk factors for TB recurrence in three categories: (i) treatment response
associated with relapse, (ii) individual vulnerability associated with both relapse and reinfec-
tion, and (iii) repeat exposure associated with reinfection. Risk factors contributing to each of
these categories are detailed below and outlined in Table 2 (adapted from Trinh et al. [3]).
7.1. Treatment response: relapse
7.1.1. Treatment regimen, adherence, and drug resistance
Incomplete bacteriologic cure, which is usually caused by irregular medication intake, is the
most common cause of relapse. Inadequate treatment regimens, poor treatment adherence,
and unrecognized drug resistance have been cited as risk factors for relapse TB infection.
Regimens with low bactericidal potency, inadequate treatment duration, inappropriate drug
choice, and undetected drug resistance all contribute to treatment failure and relapse disease.
The use of standardized regimens in the absence of full drug susceptibility testing contributes
to inadequate regimen choice and further impacts on the development of drug resistance and
relapse [3, 6, 60]. Earlier studies reporting on the association between inadequate treatment
regimen and risk for recurrent TB cited the use of thiacetazone-containing regimens. Thiace-
tazone is an antitubercular drug that was used widely in combination with isoniazid for the
treatment of TB. This agent has since been replaced by the widespread use of standardized
TB recurrence risk
Treatment response:
relapse
Individual vulnerability:
relapse or reinfection
Repeat exposure:
reinfection
1. Treatment regimen
• Inadequate treatment
• Undetected drug resistance
2. Treatment adherence
• Poor compliance
• Drug shortage
3. Drug PK/PD* and
pharmacogenomic determinants
• Poor drug penetration
• Variable PK values
• Genetic mutations that
alter drug metabolizing
enzymes
1. Individual Vulnerability
• HIV infection (CD4 count)
• Previous TB disease and residual lung
damage
• Greater area of lung tissue involved
• Positive sputum culture at 2 months
of treatment
• Diabetes Mellitus
• Extremes of Age
• Vulnerable groups and social risk
factors
• Infection with strains that have an
increased propensity for drug resis-
tance
2. Reduced local defenses
• Cigarette smoking
• Air pollution
• Silicoses
• Chronic lung disease
1. Epidemic control
• High TB preva-
lence
2. Infection control
• Clinics/hospitals/
prisons
• Public transport
• Places of sociali-
zation
3. TB contacts
• Household con-
tacts
• Social or work
contacts
• Overcrowding or
poor living condi-
tions
*PK = pharmacokinetics; PD = pharmacodynamics.
Table 2. Risk factors for TB recurrence, adapted from Trinh et al. [3].
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regimens containing rifampicin [21, 61]. Poor treatment adherence has also been reported to
drive the development of drug resistance and thus relapse. Poor adherence to anti-TB treat-
ment is associated with increased treatment duration, complex multidrug regimens, as well as
social risk factors. Other issues linked to regimen choice and adherence include substandard
drug quality and drug stock outs, and these are associated with poorly resourced, high TB-
endemic countries [3]. Recurrent TB is also associated with an increased risk of developing
drug resistance. Studies have reported an increase in acquired rifamycin-resistant TB in
patients that received rifamycin-based directly observed therapy. In both studies, the key risk
factor for rifamycin-resistance acquisition was HIV coinfection with advanced immunosup-
pression. In a cohort of 93 relapse patients with no prior evidence of MDR-TB, Chiang et al.
reported that the prevalence of overall drug resistance was 33.3% and the prevalence of MDR-
TB in the relapse patients was 12.9% [62]. Similarly, Sun et al. reported higher rate of TB
recurrence in MDR-TB patients. In a cohort of 100 MDR and 150 non-MDR TB patients, recur-
rence rates of 65/1000 and 35/1000 person-years, respectively, were reported. The increased
prevalence of drug resistance in relapse patients is exacerbated by the inefficacy of standardized
retreatment regimens and underscores the need for increased MDR-TB case detection for
retreatment patients [12].
7.1.2. Drug pharmacodynamics (PD) and pharmacokinetics (PK)
Host-specific factors such as PD, PK, and pharmacogenomics impact on the response to anti-
TB treatment. Current anti-TB treatment dosing is based on the patient’s body weight [63].
Drug concentrations and pharmacokinetics vary among patients, resulting in adverse reactions
due to toxicity as well as suboptimal drug concentrations that impact on the development of
drug resistance and relapse. Plasma concentrations of HIV and anti-TB drugs have been
reported to display wide interindividual variability associated with genetic mutations in the
respective drug-metabolizing enzymes or transporter proteins [64–66].
7.2. Individual vulnerability: relapse and reinfection
7.2.1. Individual vulnerability
7.2.1.1. HIV infection
HIV coinfection has been reported to increase the rate of recurrent TB disease, especially in
high TB-endemic settings where TB recurrence rates of up to 24.4% have been reported. A
cohort study in Malawi showed that the rates of tuberculosis relapse were similar between
HIV-positive and -negative individuals [53]. Similar results were found in a study of South
African mineworkers [41]. In contrast, several studies have reported a nearly three-fold higher
incidence of recurrent TB among HIV-positive individuals as compared to their negative
counterparts. In a review of 32 studies, Panjabi et al. reported excessive rates of recurrent TB
following the completion of treatment using standardized regimens. Among the controlled
trials included in the review, the overall recurrence rates (per 100,000 person-years) were 3010
(95% confidence interval 2230–3970) and 2290 (95% confidence interval 1730–2940), respec-
tively, at 6 and 12 months following treatment completion. Recurrence rates were reported to
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be higher for observational studies compared to controlled trials in countries with higher TB
incidence rates. In the studies reviewed, recurrence rates were found to be higher among HIV-
infected (6.7, 95% confidence interval 5.9–7.6) compared to HIV-uninfected (3.3 95% confidence
interval 2.8–3.9) individuals. In the HIV-infected group, recurrent TB was associated with low
initial CD4 T-cell count and anti-TB treatment less than 37 weeks of duration. While the
association of low initial CD4+ T-cell count and TB recurrence was unclear in this review, the
authors reported that small sample sizes lacked sufficient power to detect differences in
recurrence rates between patients with high and low CD4+ T-cell counts [5]. An earlier study
by Pulido et al. was the only study in the analysis that reported a statistically significant
relationship in a multivariate analysis. A complimentary explanation is that patients with
severe immunosuppression secondary to HIV die from other causes before TB recurs. Studies
also reported that anti-TB treatment for less than 37 weeks was the most influential predictor
of TB recurrence. The risk of TB recurrence in patients with low CD4+ T-cell counts was four
times higher than that in patients with higher CD4+ T-cell counts. This also highlights that the
six-month standard treatment regimen may be suboptimal at preventing recurrent TB in
patients with low initial CD4+ T-cell counts [67]. Chaisson et al. reported similar findings in
their review of two studies, which compared the rates of recurrent TB among HIV-infected and
HIV-uninfected individuals [7]. In an Indian cohort, Narayanan et al. reported higher rates of
recurrent TB in HIV-infected individuals compared with the HIV-uninfected group (14%
versus 9%). In addition, recurrence due to reinfection was reported in 88% of the HIV-infected
group and 9% of the HIV-uninfected group (p < 0.05). Among the recurrent isolates, patients
from the HIV-infected group were associated with more clustering of strains and increased
drug resistance [11].
7.2.1.2. Previous TB disease and residual lung damage
The severity of lung disease indicated by the presence of cavities and, in particular, residual
cavities is a significant risk factor for recurrent TB disease. Lung cavities persisting at the end
of treatment has been reported as a dominant correlate of recurrent disease in many studies
[5]. Sonnenberg et al., in a study of South African mineworkers, found that residual cavitation
was a risk factor for tuberculosis relapse [41]. The association between residual cavitation and
recurrent disease has been attributed to poor penetration of anti-TB drugs into the cavity walls
surrounding fibrotic tissue. It has also been postulated that MTB strains, like other
nontuberculous mycobacteria, may have increased propensity for the infection of previously
damaged tissue. The relationship between residual lung cavitation with recurrent TB disease
warrants further investigation. Future studies should be aimed to assess the number and size
of cavities present before and at the end of recurrent TB disease [5].
7.2.1.3. Greater area of lung tissue involved in infection
Several studies have reported that the extent of lung tissue involved in disease was a predictor
of recurrent TB disease. However, no standard measure was applied to establish the amount of
lung tissue involved in disease, and thus measures of lung area varied between studies [5].
Mallory et al. divided lung tissue into three areas, recording the number of zones with lesions.
The authors report a dose–response association between the number of lung zones with
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fibrosis and the likelihood of recurrence to strongly suggestive of a relationship [68]. Tam et al.
scored lung involvement by combining the total area of lung tissue with lesions [69].
7.2.1.4. Positive sputum culture at 2 months of treatment
Numerous studies reflect evidence in support of a positive sputum bacteriologic status during
anti-TB treatment and recurrent TB disease. These findings suggest that a positive sputum
culture at 2 months of treatment is predictive of recurrence. This association has been attrib-
uted to an inadequate response to the intensive phase of anti-TB treatment [5]. Horne et al.
conducted a systematic review and meta-analysis to assess the accuracy of positive sputum
smear or culture for predicting treatment failure or relapse in pulmonary TB. The authors
demonstrated that both sputum smear and culture during tuberculosis treatment have low
sensitivity and modest specificity for predicting failure and relapse. Although the study
represented a diverse group of patients, the individual studies had similar performance char-
acteristics [70]. Gillepsie et al. reiterated the poor predictability of culture conversion for long-
term outcomes. While two-month culture conversion is associated with relapse-free cure, this
correlation is not strong enough to reliably predict outcomes for individual patients or defin-
itively guide the selection of regimen in drug development [71].
7.2.1.5. Diabetes mellitus
Diabetes mellitus (DM) is recognized as a risk factor for the reactivation of TB infection and
relapse infection following the completion of treatment. Diabetics have been reported to have
three times higher risk of developing pulmonary TB compared to nondiabetics [72, 73]. Numer-
ous studies have reported that DM coinfection adversely affects TB treatment outcomes, which
included treatment failure, death, and relapse. In addition to the interaction between DM and
TB, the high reported prevalence of DM in MDR-TB is alarming, with approximately 10–23% of
MDR-TB patients having DM. A proposed hypothesis for this association is that altered immu-
nity accompanied with DM has an effect on MDR-TB transmission, as with other immunodefi-
ciency disease. A recent systematic review aimed to quantitatively evaluate the propensity for
patients with DM and TB to cluster according to the genotype of the infected MTB strain. While
the meta-analysis failed to show an association between TB transmission patterns in DM
patients, among the 4076 patients analyzed, 13% had DM with 27% of these patient isolates
displaying clustering. Further work is needed to address this phenomenon. These factors high-
light the need for continual monitoring of DM patients who complete treatment for incident TB
and possible use of secondary isoniazid prophylaxis treatment. In addition, comanagement for
DM-TB patients will be significant in reducing relapse in these patients [74].
7.2.1.6. Extremes of age
Young adults (15–44 years) have been reported to have the highest risk for recurrent disease
[75]. Children under 15 years and adults over 65 years have a lower risk compared to young
adults. Age is linked to default on treatment; however, no particular age has been singled out
in association with recurrence [21]. It is postulated that children have lower bacterial load as
well as increased supervision and attention to care, indicated by higher rates of treatment
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completion. There are limited data available on recurrence in children. Scaaf et al. reported 11
recurrences of TB disease in a cohort of 87 children. Of the eighty-seven children described in
the study, nine had a second episode of TB, and two of which had a third episode of confirmed
TB. Full epidemiological profiling could not be conducted, as clinical isolates representing the
first episode of TB were not available for five of the cases [48].
7.2.1.7. Vulnerable groups and social risk factors
Vulnerable groups with increased susceptibility to TB infection and recurrent TB include HIV-
coinfected patients, children, health care workers (HCWs), prisoners, homeless persons, drug
users, and close contacts of TB patients. HIV coinfection, discussed above, is associated with
high rates of recurrent TB. Children contribute a significant proportion of the TB disease
burden and suffer severe tuberculosis-related morbidity and mortality, particularly in endemic
areas. HCWs are placed at a higher risk for the acquisition of nosocomially acquired TB. Risk
factors include poor or malfunctioning infection control measures and poor utilization of
personal protective equipment. There is also a significant risk of secondary hospital outbreaks
related to undetected and untreated TB. Prisoners, homeless persons, and drug users are at
higher risk for TB and recurrent infections as they represent underserved populations. These
populations are also more likely to be coinfected with HIV and are more difficult to manage
and treat adherently. Imprisonment has been recognized as a significant risk factor for TB
transmission. Household contacts of TB patients have been reported to be at high risk for
developing TB, including drug-resistant TB. Preventative therapy remains the most significant
tool to reduce the risk of TB infection among high-risk individuals [3, 79].
7.2.1.8. Infection with certain strain types
Infection with strains of the Beijing genotype has been associated with unfavorable TB outcomes.
The Beijing genotype has gained particular attention due to reports on its association with drug-
resistant TB in outbreaks and population-based studies [3]. Huyen et al. demonstrated that the
Beijing genotype was associated with an increased rate of relapse in Vietnam. Among a cohort of
1068 patients that were followed up for 18 months, 23 cases of relapse occurred, linked to this
genotype [83]. Nguyen et al. reported similar findings for the same settings. However, this strain
type has been reported to account for 40% of TB cases in Vietnam, and this may represent high
transmission rates rather than the success of the strain [84].
7.2.2. Reduced local defenses
7.2.2.1. Tobacco smoking
A systematic review by Lin et al. demonstrated that tobacco smoke is consistently associated
with increased risk of TB infection. In comparison to nonsmokers, smoking increases the risk of
developing active TB and mortality. Smoking has been reported to affect baseline severity,
bacteriologic response, treatment outcome, and relapse in TB. Smoking has also been reported
to alter the lung immune responses to MTB, contributing to a higher susceptibility to individual
TB infection. Chronic exposure to tobacco and air pollutants impairs the normal clearance of
secretions on the bronchial mucosal surface and may allowMTB to evade the early host immune
defenses. Smoke also inhibits the activity of alveolar macrophages by reducing the phagocytic
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ability of the cells. Lower levels of pro-inflammatory cytokines have also been reported for
smokers [76]. Leung et al. evaluated the impact of smoking on TB outcomes by monitoring
16,435 patients receiving anti-TB treatment at chest clinics in Hong Kong. Overall, 16.7% of
negative treatment outcomes were attributed to smokers, with the key contributor being default
and death in smokers. Among 13,349 patients who were successfully treated for TB, 426 cases of
relapse were detected. They reported a clear gradient (hazard ratios of 1.00, 1.33, and 1.63) of
relapse risk from nonsmokers to previous smokers and current smokers, with an overall popu-
lation attributable risk of 19.4% (current smokers: 12.2%; previous smokers: 7.2%) [77].
7.2.2.2. Air pollution
In addition to tobacco smoke, environmental exposures have been associated with an increased
risk for developing TB. Air quality, which is impacted by atmospheric pollution and carbon
monoxide, has been reported to induce bacillary reactivation and to increase the incidence of TB
[76]. De Castro Fernandes et al. reported that air pollution was directly related to TB incidence in
Brazil. Other studies conducted in the US and Russia also reported a link between the concen-
tration of smoke, suspended particulate matter, and TB in relation to carbon dioxide and nitric
oxide levels. Air pollution generated by traffic in Taiwan, linked to sulfur dioxide, ozone, and
carbon monoxide, was linked to culture-confirmed TB. Similarly, a study conducted in South
Korea revealed that exposure to sulfur dioxide increased the risk of TB by 7%. Indoor air
pollution, resulting from the use of solid fuels for cooking, has been recognized as a risk factor
for TB disease. The role of these factors in recurrent TB requires further study [78].
7.2.2.3. Chronic lung disease
Chronic lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, and
interstitial lung diseases such as silicosis, have been recognized as risk factors for the development
of tuberculosis. Studies have demonstrated that 25–30% of silicosis patients develop TB with a
relative risk for TB of 2.8 in silicosis patients when compared to the general population. However,
there are limited data on the role of chronic lung disease in recurrent TB [79]. Pettit et al. reported
an increased risk of TB recurrence with chronic lung disease (OR 5.28, 95% CI 1.16–2404, P = 0.03).
However, a major limitation of the study was the low recurrence rate in the cohort, as the study
was conducted in a low TB-incidence setting. Conversely, reports now suggest that a history of TB
may lead to chronic lung disease, particularly COPD and bronchiectasis [80]. A recent systematic
review by Byrne et al. reported a strong and consistent positive association between a history of
TB and the presence of chronic respiratory diseases, including COPD and bronchiectasis. This
suggests that the development of chronic lung disease following TB increases the risk of recurrent
TB infection. In addition, tobacco smoking is an attributable risk factor for the development of
COPD and thus may be a link in the development of TB and recurrent TB [80].
7.3. Repeat exposure: reinfection
7.3.1. Epidemic control, infection control, and close TB contacts
On a public health level, recurrent tuberculosis accounts for a considerable proportion of TB
cases in weak TB control programs and contributes to ongoing transmission of infection to
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close contacts in the home environment, community, and health care facilities. In high-
incidence settings, recurrence has been attributed mainly to reinfection, with up to 75% of
cases being attributed to reinfection. Reinfection represents a constant risk over time in
patients with a history of TB. High reinfection rates have important implications for TB control
strategies and underscore the need to reduce transmission in the community and the urgent
need for rapid diagnosis and treatment of TB [3, 7, 8]. Coupled with comorbidities such HIV
and diabetes that result in reduced immunity, such populations become more susceptible to
infection and reinfection [5, 74]. Recent studies have indicated that transmission events are
most likely to occur with the community and not within the household. A recent report on an
XDR-TB cohort in South Africa demonstrated that 19% of patients that were discharged were
linked to secondary case of TB [81]. Shah et al. reported that XDR-TB in the KwaZulu-Natal
province of South Africa was linked to transmission of disease as opposed to inadequate drug
treatment for MDR-TB. The authors demonstrated person-to-person and hospital-based epide-
miological links [82]. Taken together, these studies highlight that epidemic control requires an
increased focus on interrupting transmission and the need to establish community-based
containment strategies, including voluntary long-term community stay facilities and palliative
care in tuberculosis-endemic settings [81, 82].
8. Immunopathogenesis of recurrent TB
MTB has evolved with the human host over decades and has successfully evaded natural
immune defenses, progressing to a stage of relative dormancy. Successful control of the TB
epidemic would be best achieved with an effective preventative vaccine; however, the incom-
plete understanding of natural correlates of protection that an effective vaccine should emulate
has hampered vaccine development. The continuum of the host-pathogen interaction follow-
ing MTB infection to TB disease extends across the innate immune, adaptive immune, and
quiescent and active replicating phases of infection. In approximately 5% of patients, this cycle
extends beyond successful treatment completion when the cycle of TB recurrence may occur.
In this subset of patients, persistence of MTB results in relapse, whereas in others, reinfection
with MTB results in subsequent disease. Biomarkers indicative of the spectrum of TB disease
have been described; however, there are limited reports on biomarkers of recurrent TB [85].
The matter of whether or not the first episode of TB imparts some measure of immunity has
not been explicitly established but is assumed to have an impact [86].
Thobakgale et al. conducted a study in a cohort of HIV-coinfected patients with a history of
previous successful TB treatment, which aimed to identify innate immune correlates associ-
ated with TB recurrence. Production of interleukin-1 (IL-1) beta by innate immune cells fol-
lowing ex-vivo stimulation with Toll-like receptor (TLR) and Bacillus Calmette-Guérin (BCG)
stimulants correlated with differential TB recurrence outcomes. Elevated IL-1 beta production
by monocytes following TLR stimulation was protective against TB recurrence. In contrast,
production of IL-1 beta by monocytes and myeloid dendritic cells following stimulation with
BCG was associated with an increased risk for recurrent TB. These findings highlight signifi-
cant differences in the host immune response to TB and require validation in larger cohort of
patients [87]. Sivro et al. studied the role of plasma cytokine correlates of TB recurrence in a
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cohort of HIV-coinfected patients with a history of previous successful TB treatment. The study
reported higher levels of plasma levels of interleukin-6 (IL-6), IL-1 beta, and soluble IL-1
receptor antagonist were associated with increased risk of TB recurrence, while plasma inter-
feron beta levels decreased the risk of TB recurrence. These findings highlight that the markers
of systemic inflammation, which are also involved in the rapid progression of HIV, predict TB
recurrence in HIV-coinfected patients [88].
Gene expression profiling of ex-vivo whole blood specimens has demonstrated transcriptomic
changes in patients with recurrent TB as compared to healthy counterparts, including signifi-
cant changes in gene expression during successful treatment. Mistry et al. identified a gene
signature that identified a set of genes in patients with recurrent TB that clearly distinguished
this group from patients who remained cured [89]. Cliff et al. reported on the expression of 668
genes in patients who experience recurrent TB in comparison to those who remained cured,
with the differences lasting up to 4 weeks following TB diagnosis. The upregulated genes were
involved in cytotoxic cell-mediated killing. These findings suggest that patients who subse-
quently relapse exhibit altered immune responses, including robust cytolytic responses to MTB
in vitro at diagnosis, compared to patients who achieved cure [90]. Thompson et al. reported on
several clinically significant host-blood RNA signatures that predicted TB treatment outcomes,
stratifying patients according to their risk of treatment failure. The signature correlated with
pulmonary inflammatory states measured by PET-CT scanning and can complement current
sputum-based testing methods for a rapid and accurate alternate testing method [91].
De Steenwinkel et al. reported on the differences between primary and recurrent TB in relation to
changes in mycobacterial load in infected organs, immunopathology, and plasma cytokine levels
using a murine model. In comparison to primary TB, recurrent TB was associated with lower
mycobacterial load in the lung, spleen, and liver. Significantly lower levels of tumor necrosis
factor-alpha, interferon-alpha, IL-6, MIG/CXCL9, IP-10/CXCL10, and lL-17 were observed for
recurrent TB. In addition, memory Th-1 cells were locally and systemically expanded and
congregated in the lung during recurrent TB, promoting efficient control of MTB growth [92].
9. Treatment of recurrent TB
Current WHO guidelines advocate the use of the standard six-month TB treatment regimen for
all new and retreatment drug-susceptible TB cases. This regimen comprises a two-month inten-
sive treatment of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by a four-
month continuation phase of isoniazid and rifampicin. They further recommend the use of rapid
molecular-based drug susceptibility testing (DST) to guide regimen choice for all retreatment TB
patients. However, in settings where rapid DSTs are not available, empiric treatment is advised
based on the following recommendations. Patients with a high likelihood of MDR-TB should be
initiated on an empiric MDR-TB regimen using clinical discretion or if the patients have relapsed
or defaulted on treatment after a second or subsequent course of treatment. The second recom-
mendation is a retreatment regimen of 2 months of isoniazid, rifampicin, pyrazinamide, etham-
butol, and streptomycin, followed by 1 month of isoniazid, rifampicin, pyrazinamide, and
ethambutol and finally 5 months of isoniazid, rifampicin, and ethambutol [93].
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It is well recognized by many that a stratified medicine approach would be a desirable approach
for the retreatment of TB. However, the challenge associated with a stratified medicine approach
is in identifying groups that are eligible for a longer treatment regimen [94, 95]. There are many
identifiable risk factors associated with recurrence, such as a baseline cavitation and month-two
smear status that may indicate the need for increasing treatment duration. However, the recent
REMoxTB and RIFQUIN studies, which evaluated new regimens aimed at shortening treatment
duration for drug-susceptible TB, reported a relapse risk of 2.8 and 3.2%, respectively, with an 18-
month follow-up period [96]. Among the factors attributed to poor success of the new regimens
in the REMoxTB study, it was suggested that baseline cavitation modified the differences
between the results. In contrast, 91% (n = 386) of the patients on the standard 6-month regimen
with baseline cavitation had a favorable outcome at the end of the follow-up period [71]. A
systematic review by Menzies et al. related to treatment outcomes of rifampicin-containing
regimens of various durations showed only a modest benefit in regimens given for nine or more
months in comparison to the standard six-month treatment. Thus, the benefit of a stratified
treatment approach remains debatable [97].
In the context of recurrence due to relapse or reinfection disease, a different treatment approach
is required. In the case of reinfection, this can be considered as a new primary infection, and thus,
standard regimens may be effective. In contrast, relapse is associated with an increased risk of
drug resistance due to the persistence of the original infecting strain under suboptimal treatment.
Collectively, all the factors mentioned here underscore the significance an individualized treat-
ment approach guided by DST [92, 93].
10. Preventative therapy for recurrent TB
Active TB disease has been shown to be preventable by the use of primary preventative
therapy (pPT), which aims to prevent the first episode of TB in individuals in whom active TB
has been excluded. The average preventative effect of pPT in HIV-uninfected individuals is a
60% reduction in the incidence of recurrent TB, while in HIV-infected individuals, the average
effect is a 30% reduction in recurrent TB [98, 99]. A potential approach to prevent recurrent TB
is secondary preventative therapy (sPT), by continuing the use of anti-TB therapy following
completion of treatment for TB. sPT aims to reduce the incidence of recurrent TB in TB patients
who have completed treatment for their most recent episode of TB [100]. The World Health
Organization (WHO) recommends the use of isoniazid preventative therapy (IPT) in patients
with HIV infection.
The TEMPRANO (trial of early antiretrovirals and isoniazid preventative therapy in Africa)
study demonstrated that the use of 6 months of IPT combined with early antiretroviral therapy
reduced the risk of severe HIV-related comorbidities by 44% and all-cause mortality by 33%
[101]. Kabali et al. reported reduced mortality in tuberculin skin test (TST)-positive patients
with CD4+ T-cell counts >200 cells/mm3 in a Tanzanian cohort [102]. Charalambous et al.
demonstrated a 49% reduction in mortality that remained significant even in patients who
had a past history of TB. However, in high-burden countries and in TST-positive patients, a
36-month course of IPT has been recommended. The 36-month IPT course demonstrated a 74%
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reduced risk of active TB and 68% reduction in mortality compared to the 6-month course
[103]. The REMEMBER (reducing early mortality and early morbidity by empirical tuberculo-
sis treatment regimens) study aimed to assess whether empirical TB treatment will reduce
early mortality compared with IPT in patients with advanced HIV disease initiating antiretro-
viral therapy. Overall, empirical TB therapy did not reduce early mortality compared to IPT.
However, the low mortality rate in the study underscores the need for TB screening and IPT in
patients with HIV [104].
In their review of four studies, Bruin et al. reported the effect of sPT for the prevention of
recurrent TB in HIV-infected individuals and the context in which the preventative approach
may be applied. All four studies reported that sPT decreased incidence of recurrent TB in
comparison to nontreatment groups. Relative reductions varied from 55.0 to 82.1%. However,
only one of the four studies reported a significant effect on overall survival [100]. Perriens et al.
described the use of isoniazid (INH) and rifampicin (RIF) twice weekly for an additional
6 months in comparison to a placebo. Patients receiving sPT were reported to be significantly
less likely to develop recurrent TB compared to the placebo group (relative risk 0.21, p < 0.01)
[105]. Haller et al. assessed the effectiveness of INH and sulphadoxine-pyrimethamine as sPT.
The relative rate for the incidence of recurrent TB in patients receiving additional treatment
(n = 134) and those not (n = 129) was 0.30 (95% confidence interval: 0.09–0.94) [106]. Fitzgerald
et al. assessed the use of INH for an additional year following the completion of initial
treatment compared to a placebo group. The intervention significantly reduced the incidence
of recurrent TB from 7.8 per 100 person-years to 1.4 per 100 person-years (relative risk 0.18,
confidence interval: 0.04–0.83) [107]. Churchyard et al. assessed the effect of INH in combina-
tion with cotrimoxazole versus cotrimoxazole only or no intervention in HIV-infected gold
miners in South Africa. The rate ration for the development of recurrent TB in comparing the
groups with INH and the group without INH was 0.45 (95% confidence interval: 0.26–0.78)
[108]. As with pPT, the ideal duration and drug choice remain unclear. In all four studies, the
duration of treatment varied from 6 to 24 months. The duration of effectiveness of sPT could
not be assessed due to the short follow-up periods of the studies. None of the studies included
made a distinction between relapse and reinfection as the mechanism of recurrent TB. Further-
more, Haller et al. and Fitzgerald et al. diagnosed recurrent TB by clinical assessment only,
which could indicate overestimation of recurrent TB [106, 107].
11. Conclusion and future perspectives
Recurrent TB poses a major threat to TB control programs, especially given the persistent
vulnerability of HIV-infected patients to tuberculosis, and the higher propensity of recurrent
disease being due to resistant MTB strains. In the absence of large-scale population-based
surveillance reports, the overall rate of recurrent TB following completion of treatment is
significantly underestimated. Current estimates are based on a combination of randomized
controlled trials and observational studies, with reliability estimates of the former limited by
study follow-up time, and the latter prominently demonstrating higher rates of recurrence.
Under clinical trial conditions, adherence rates are better; treatment facilities are more accessi-
ble and incorporate adequate follow-up after treatment, leading to improved treatment
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outcomes and lower rates of recurrence. In contrast, observational studies reflect the operating
environment of most high-burden TB facilities.
Distinguishing between relapse and reinfection is of paramount importance in addressing the
burden of recurrent TB disease. High rates of relapse demand renewed interventions to
improve individual patient care while high rates of reinfection demand improved infection
and epidemic control measures. Urgent attention is required to address challenges of adher-
ence, such as social and health care worker support systems and step-down management
facilities. With the heightened risk or recurrent TB in HIV, TB screening should be conducted
at all ART follow-up visits, and TB preventative therapy should be implemented in all HIV-
positive patients completing TB treatment. Enhanced infection control strategies should be
implemented in clinical and community settings to reduce ongoing transmission of TB. There
has been considerable disparity in the studies reporting on the role of relapse versus reinfec-
tion. Further large-scale studies are required to address the role of relapse and reinfection as
well as the role of mixed infections in recurrent TB.
This review highlights well-established principles in TB control. TB recurrence rates are grossly
underestimated and are highest in those with extensive pulmonary disease and cavitary
disease and in those with comorbidities such as HIV infection and diabetes. Active case
findings among these patients within 12 months of completing treatment would enable early
detection of TB recurrence. Enhanced treatment options, such as intensified initial treatment,
extension of treatment, and secondary preventative therapy for patients presenting with mul-
tiple risk factors will prevent recurrent TB infection. Understanding the immunological corre-
lates that offer protection against recurrent TB will also play a role in host-directed therapy and
reducing recurrent TB.
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